2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

11:00AM-12:30PM: Abstract Number: 914

Longitudinal Blood Transcriptomics Uncovers Immune Networks Associated with Complications in Lupus Pregnancy

Plenary Session I: Discovery 2016

11:00AM-12:30PM: Abstract Number: 910

Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study

Plenary Session I: Discovery 2016

11:00AM-12:30PM: Abstract Number: 912

Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease

Plenary Session I: Discovery 2016

2:30PM-4:00PM: Abstract Number: 927

2015 ACR/ARHP Workforce Study in the United States: Pediatric Rheumatologist Supply and Demand Projections for 2015-2030

Health Services Research I: Workforce and Quality of Care in Rheumatology

2:30PM-4:00PM: Abstract Number: 928

2015 ACR/ARHP Workforce Study in the United States: A Maldistribution of Adult Rheumatologists

Health Services Research I: Workforce and Quality of Care in Rheumatology

2:30PM-4:00PM: Abstract Number: 947

A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results

Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 942

A Nationwide Experience with the Off Label Use of Interleukin 1 Targeting Treatment in Familial Mediterranean Fever Patients

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 951

A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months’ Clinical Outcomes from the Danbio Registry

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Treatment Strategies

2:30PM-4:00PM: Abstract Number: 944

A New Syndrome in the Spectrum of Cryopyrin-Associated Periodic Syndromes (CAPS) Caused By the Novel R918Q NLRP3 Mutation

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 978

A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis

Vasculitis I: Novel Approaches to Therapy

2:30PM-4:00PM: Abstract Number: 979

A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Takayasu’s Arteritis

Vasculitis I: Novel Approaches to Therapy

2:30PM-4:00PM: Abstract Number: 952

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Treatment Strategies

2:30PM-4:00PM: Abstract Number: 940

A Trial of XmAb®5871, a Reversible Inhibitor of CD19+ Cells, in IgG4-Related Disease

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 941

An International, Multi-Specialty Validation Study of the IgG4-Related Disease Responder Index

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 918

Anergic B Cells May Preserve Peripheral Tolerance in Lupus-Prone Congenic Mice

B Cell Biology and Targets in Autoimmune Disease I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].